Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by PRAJNAN DAS and GEORGE J CHANG.
PRAJNAN DAS
Connection Strength
3.571
GEORGE J CHANG
  1. The prognostic impact of tumor deposits in colorectal cancer: More than just N1c. Cancer. 2024 Dec 01; 130(23):4052-4060.
    View in: PubMed
    Score: 0.247
  2. Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clin Colorectal Cancer. 2022 03; 21(1):e28-e37.
    View in: PubMed
    Score: 0.201
  3. Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):595-600.
    View in: PubMed
    Score: 0.161
  4. Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation. Am J Clin Oncol. 2018 07; 41(7):632-637.
    View in: PubMed
    Score: 0.161
  5. Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal. Am J Clin Oncol. 2017 Dec; 40(6):555-560.
    View in: PubMed
    Score: 0.154
  6. Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma. J Gastrointest Oncol. 2017 Dec; 8(6):990-997.
    View in: PubMed
    Score: 0.154
  7. Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer. J Clin Oncol. 2017 Aug 10; 35(23):2631-2638.
    View in: PubMed
    Score: 0.150
  8. Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):455-464.
    View in: PubMed
    Score: 0.148
  9. Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. Radiother Oncol. 2017 01; 122(1):146-151.
    View in: PubMed
    Score: 0.145
  10. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):301-5.
    View in: PubMed
    Score: 0.117
  11. Metformin use and improved response to therapy in rectal cancer. Cancer Med. 2013 Feb; 2(1):99-107.
    View in: PubMed
    Score: 0.110
  12. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012 May 20; 30(15):1770-6.
    View in: PubMed
    Score: 0.104
  13. Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. Cancer. 2011 Aug 15; 117(16):3713-22.
    View in: PubMed
    Score: 0.096
  14. Long-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann Surg Oncol. 2010 Nov; 17(11):2863-9.
    View in: PubMed
    Score: 0.092
  15. Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. Int J Radiat Oncol Biol Phys. 2010 May 01; 77(1):60-5.
    View in: PubMed
    Score: 0.087
  16. A twenty-year experience with adenocarcinoma of the anal canal. Dis Colon Rectum. 2009 Aug; 52(8):1375-80.
    View in: PubMed
    Score: 0.087
  17. Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. Int J Radiat Oncol Biol Phys. 2009 Jul 01; 74(3):818-23.
    View in: PubMed
    Score: 0.083
  18. Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2008 Jul 15; 71(4):1175-80.
    View in: PubMed
    Score: 0.078
  19. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 2007 May 01; 109(9):1750-5.
    View in: PubMed
    Score: 0.074
  20. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):794-800.
    View in: PubMed
    Score: 0.074
  21. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1378-83.
    View in: PubMed
    Score: 0.071
  22. Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol. 2006 Jun; 29(3):219-24.
    View in: PubMed
    Score: 0.069
  23. Patient-Reported Sexual Function, Bladder Function and Quality of Life for Patients with Low Rectal Cancers with or without a Permanent Ostomy. Cancers (Basel). 2023 Dec 28; 16(1).
    View in: PubMed
    Score: 0.059
  24. Salvage Treatment of Recurrent or Persistent Anal Squamous Cell Carcinoma: The Role of Multi-modality Therapy. Clin Colorectal Cancer. 2024 03; 23(1):85-94.
    View in: PubMed
    Score: 0.059
  25. Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer. Cancers (Basel). 2023 Mar 10; 15(6).
    View in: PubMed
    Score: 0.056
  26. Patient-reported Bowel Function and Bowel-related Quality of Life After Pelvic Radiation for Rectal Adenocarcinoma: The Impact of Radiation Fractionation and Surgical Resection. Clin Colorectal Cancer. 2023 06; 22(2):211-221.
    View in: PubMed
    Score: 0.055
  27. A phase II randomized double blinded trial evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer. J Gastrointest Oncol. 2022 Dec; 13(6):2938-2950.
    View in: PubMed
    Score: 0.055
  28. Patient-Reported Bowel and Urinary Function in Long-Term Survivors of Squamous Cell Carcinoma of the Anus Treated With Definitive Intensity Modulated Radiation Therapy And Concurrent Chemotherapy. Int J Radiat Oncol Biol Phys. 2022 09 01; 114(1):78-88.
    View in: PubMed
    Score: 0.052
  29. Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. Oncologist. 2022 02 03; 27(1):40-47.
    View in: PubMed
    Score: 0.051
  30. Intraoperative Radiation After Pelvic Short Course Radiation-Based Total Neoadjuvant Therapy for Patients With Rectal Adenocarcinoma at High Risk for Local Recurrence. Clin Colorectal Cancer. 2022 09; 21(3):204-211.
    View in: PubMed
    Score: 0.051
  31. CEA as a blood-based biomarker in anal cancer. Oncotarget. 2021 May 25; 12(11):1037-1045.
    View in: PubMed
    Score: 0.049
  32. Pathologic Response and Postoperative Complications After Short-course Radiation Therapy and Chemotherapy for Patients With Rectal Adenocarcinoma. Clin Colorectal Cancer. 2020 06; 19(2):116-122.
    View in: PubMed
    Score: 0.045
  33. A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. Clin Colorectal Cancer. 2019 12; 18(4):301-306.
    View in: PubMed
    Score: 0.043
  34. Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. Am J Clin Oncol. 2017 Jun; 40(3):277-282.
    View in: PubMed
    Score: 0.037
  35. Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum. Am J Clin Oncol. 2017 Apr; 40(2):163-166.
    View in: PubMed
    Score: 0.037
  36. Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. Oncologist. 2015 Nov; 20(11):1247-52.
    View in: PubMed
    Score: 0.033
  37. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget. 2014 Nov 30; 5(22):11133-42.
    View in: PubMed
    Score: 0.031
  38. Intraoperative radiation therapy for locally advanced primary and recurrent colorectal cancer: ten-year institutional experience. J Surg Oncol. 2014 Jun; 109(7):652-8.
    View in: PubMed
    Score: 0.030
  39. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer. 2013 Dec 15; 119(24):4231-41.
    View in: PubMed
    Score: 0.029
  40. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Cancer. 2013 Nov 01; 119(21):3769-75.
    View in: PubMed
    Score: 0.029
  41. Intraoperative radiotherapy in colorectal cancer: systematic review and meta-analysis of techniques, long-term outcomes, and complications. Surg Oncol. 2013 Mar; 22(1):22-35.
    View in: PubMed
    Score: 0.027
  42. Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann Surg. 2010 Feb; 251(2):261-4.
    View in: PubMed
    Score: 0.022
  43. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):824-30.
    View in: PubMed
    Score: 0.021
  44. Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer. Gastrointest Cancer Res. 2007 Mar; 1(2):44-8.
    View in: PubMed
    Score: 0.018
  45. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):762-71.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.